Skip to main content

NG-641-03 Phase 1 study of NG-641 plus nivolumab in metastatic or advanced epithelial tumours

NCT05043714

Phase 1 study of NG-641 plus nivolumab in metastatic or advanced epithelial tumours

Principal Investigator

Guru Sonpavde

Sponsor

PsiOxus Therapeutics Ltd

The purpose of this research study is to find out the effects, good and/or bad, treatment with the study drug and nivolumab has on you and your cancer and to find out what happens to the study drug and the proteins it makes in your body. Male or female patients aged 18 years or older and have metastatic or advanced epithelial cancer may be eligible to participate.

This study is currently enrolling.